1445856-13-2

Basic information

• Product Name: Tert-Butyl 5-Bromo-1H-Pyrrolo[2,3-C]Pyridine-1-Carboxylate
• Synonyms: Tert-Butyl 5-Bromo-1H-Pyrrolo[2,3-C]Pyridine-1-Carboxylate;5-Bromo-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 1445856-13-2
• Molecular Formula: C12H13BrN2O2
• Molecular Weight: 297.14782
• Mol File: 1445856-13-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tert-Butyl 5-Bromo-1H-Pyrrolo[2,3-C]Pyridine-1-Carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-Butyl 5-Bromo-1H-Pyrrolo[2,3-C]Pyridine-1-Carboxylate(1445856-13-2)
• EPA Substance Registry System: Tert-Butyl 5-Bromo-1H-Pyrrolo[2,3-C]Pyridine-1-Carboxylate(1445856-13-2)

Safety Data

• Hazardous Substances Data: 1445856-13-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1215387-58-8 5-bromo-1H-pyrrolo[2,3-c]pyridine 

Relevant articles and documents

2 Tyrosine kinase mediated signal transduction inhibitors

Disclosed herein are compounds of Formula (), and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X, X, X, X, X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors

A series of 4-azaindole-containing p21-activated kinase-1 (PAK1) inhibitors was prepared with the goal of improving physicochemical properties relative to an indole starting point. Indole 1 represented an attractive, non-basic scaffold with good PAK1 affinity and cellular potency but was compromised by high lipophilicity (c log D = 4.4). Azaindole 5 was designed as an indole surrogate with the goal of lowering log D and resulted in equipotent PAK1 inhibition with a 2-fold improvement in cellular potency over 1. Structure–activity relationship studies around 5 identified additional 4-azaindole analogs with superior PAK1 biochemical activity (Kia 20-fold decrease in unbound clearance in mouse PK studies for azaindole 5 relative to indole 1.

2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein A, Rla, Rlb, R2, R3, R4, R5, R6, R7, Rs, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders